Biotech Values

[genisi]

>Lack of increases in rash and pruritis was also a good sign. I think docs and patients would trade some efficacy for less rash and anal pruritis.<

On the other hand discontinuations due to other AE were up from the 11 and 15% reported at EASL:
"Treatment discontinuations due to adverse events (fatigue, anemia,nausea and headache) were between 9 and 19 percent for patients in the boceprevir arms, compared to 8 percent for the control arm."

BTW, did SGP say which arm had the 9% discontinuations? I suppose it was the one with the highest SVR rate of 74%.